Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is closely associated with coronary and cerebrovascular disease. Current treatment practice largely focuses on both lifestyle modifications and the use of statins, antihypertensives, and antiplatelet agents as cornerstone therapies to prevent events such as MI and stroke in these patients. The emergence of PCSK9 inhibitors to achieve aggressive LDL cholesterol lowering on top of statins is another therapeutic option for PAD patients.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed PAD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PAD patients?
- What percentage of PAD patients receive drug therapy within six months of diagnosis, and how quickly do they receive it?
- What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PAD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with PAD?
- Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithm | Peripheral Arterial Disease | US | January 2019
Author(s): Pallavi Malik, M.Sc
Pallavi Malik is a business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Biotechnology, and a Bachelor's degree in Science from the Panjab University, Chandigarh, India. Prior to joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve. Her role involved in-depth scientific secondary research, and competitive intelligence across multiple domains (such as oncology, ophthalmology and CVD) including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, competitor benchmarking, and opportunity assessment.